Back to Search Start Over

Methyltransferase like 3 inhibition limits intrahepatic cholangiocarcinoma metabolic reprogramming and potentiates the efficacy of chemotherapy.

Authors :
Gao J
Fang Y
Chen J
Tang Z
Tian M
Jiang X
Tao C
Huang R
Zhu G
Qu W
Wu X
Zhou J
Fan J
Liu W
Shi Y
Source :
Oncogene [Oncogene] 2023 Aug; Vol. 42 (33), pp. 2507-2520. Date of Electronic Publication: 2023 Jul 07.
Publication Year :
2023

Abstract

N <superscript>6</superscript> -methyladenosine (m <superscript>6</superscript> A) RNA methylation and its associated methyltransferase like 3 (METTL3) are involved in the development and maintenance of various tumors. The present study aimed to evaluate the cross-talk of METTL3 with glucose metabolism and reveal a novel mechanism for intrahepatic cholangiocarcinoma (ICC) progression. Real-time quantitative PCR, western blotting, and immunohistochemistry analyses suggested that METTL3 was highly expressed in ICC, which was correlated with poor patient prognosis. Immunoprecipitation sequencing of m <superscript>6</superscript> A-RNA showed that METTL3 upregulated m <superscript>6</superscript> A modification of NFAT5, which recruited IGF2BP1 for NFAT5 mRNA stabilization. Elevated expression of NFAT5 increased the expression of the gluconeogenesis-related genes GLUT1 and PGK1, resulting in enhanced aerobic glycolysis, proliferation, and tumor metastasis of ICC. Moreover, higher METTL3 expression was observed in tumor tissues of ICC patients with activated ICC glucose metabolism. Importantly, STM2457, a highly potent METTL3 inhibitor, which inhibited METTL3 activity and acted synergistically with gemcitabine, suggests that reprogramming RNA epigenetic modifications may serve as a potential therapeutic strategy. Overall, our findings highlighted the role of METTL3-mediated m <superscript>6</superscript> A modification of NFAT5 in activating glycolytic reprogramming in ICC and proposed that the METTL3/NFAT5 axis was a clinical target for the management of ICC chemoresistance by targeting cancer glycolysis.<br /> (© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)

Details

Language :
English
ISSN :
1476-5594
Volume :
42
Issue :
33
Database :
MEDLINE
Journal :
Oncogene
Publication Type :
Academic Journal
Accession number :
37420030
Full Text :
https://doi.org/10.1038/s41388-023-02760-0